Iterum Therapeutics plc Ordinary Share (ITRM) Stock Price
ITRMStock
$0.00+76.25%52W
Market Cap—
P/E—
PEG Ratio—
Div yield—
Beta-0.98
ITRM Share Price Chart
Favorite Metrics
Price vs S&P 500 (26W)-107.58%
Price vs S&P 500 (4W)-99.37%
VGM Score45.19
ITRM Analyst Recommendations
Feb 2026
Mar 2026
Apr 2026
May 2026
4.13
4.13
2.17
2.17
Industry Peers — Pharmaceuticals(571)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
ITRMIterum Therapeutics plc Ordinary Share | B | — | D | $0.00 |
| LLYEli Lilly & Co. | D | B | B | $1233.66 |
| JNJJohnson & Johnson | D | C | B | $273.14 |
| ABBVABBVIE INC. | D | C | B | $265.79 |
| MRKMerck & Co., Inc. | D | C | A | $156.45 |
| NVSNovartis AG | C | C | C | $159.98 |
| AZNAstraZeneca PLC | C | B | C | $169.66 |
| NVONovo-Nordisk A/S | B | C | C | $48.66 |
| ABTAbbott Laboratories | C | C | B | $116.13 |
| PFEPfizer Inc. | C | D | C | $28.57 |
| VRTXVertex Pharmaceuticals Inc | D | C | B | $552.85 |
About Iterum Therapeutics plc Ordinary Share
Iterum Therapeutics is a pharmaceutical company commercializing Orlynvah, an oral-branded penem antibiotic approved in the United States for treating complicated urinary tract infections. Orlynvah has the potential to be the first and only oral and intravenous branded penem available globally. The company targets drug-resistant bacterial infections, addressing a significant unmet medical need.